FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311373364> ?p ?o ?g. }

• W4311373364 endingPage "6139" @default.
• W4311373364 startingPage "6139" @default.
• W4311373364 abstract "The present study clarified the prognosis of intermediate-stage hepatocellular carcinoma (HCC) patients who received lenvatinib (LEN) followed by transcatheter arterial chemoembolization (TACE) on demand. We retrospectively evaluated 88 intermediate-stage HCC patients who received LEN. The median age was 74 (range: 47–92) years old, 67 patients were male, and 82 were classified as Child-Pugh A. LEN was administered until disease progression or discontinuation due to adverse events (AEs). The mean duration of LEN treatment was 7.0 months. The response and disease control rates were 51.1% and 89.8%, respectively. The median progression-free survival and overall survival (OS) after the initiation of LEN were 6.8 months and 29.9 months, respectively. The OS in patients for whom LEN was re-administered after TACE (TACE-LEN) was better than that in patients who received other therapies (e.g., only TACE, TACE-other therapy, or only other therapy) even with propensity score matching (p = 0.008). A Cox proportional hazard analysis showed that TACE-LEN was most strongly associated with the OS (hazard ratio: 0.083, 95% confidence interval: 0.019–0.362, p = 0.001). LEN was administered for approximately 11.1 months after TACE. In intermediate-stage HCC patients who can tolerate LEN without discontinuation due to AEs, TACE-LEN may prolong the prognosis." @default.
• W4311373364 created "2022-12-25" @default.
• W4311373364 creator A5007520215 @default.
• W4311373364 creator A5016290433 @default.
• W4311373364 creator A5019218504 @default.
• W4311373364 creator A5021905751 @default.
• W4311373364 creator A5028776907 @default.
• W4311373364 creator A5028796603 @default.
• W4311373364 creator A5049296252 @default.
• W4311373364 creator A5061244847 @default.
• W4311373364 creator A5061536411 @default.
• W4311373364 creator A5061849776 @default.
• W4311373364 creator A5066490288 @default.
• W4311373364 creator A5071201254 @default.
• W4311373364 creator A5073675407 @default.
• W4311373364 creator A5074378971 @default.
• W4311373364 creator A5074394178 @default.
• W4311373364 creator A5090675713 @default.
• W4311373364 date "2022-12-13" @default.
• W4311373364 modified "2023-09-26" @default.
• W4311373364 title "Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma" @default.
• W4311373364 cites W1573363574 @default.
• W4311373364 cites W1969947714 @default.
• W4311373364 cites W1971837077 @default.
• W4311373364 cites W1996703005 @default.
• W4311373364 cites W2006202974 @default.
• W4311373364 cites W2019294726 @default.
• W4311373364 cites W2147172608 @default.
• W4311373364 cites W2151600653 @default.
• W4311373364 cites W2179494416 @default.
• W4311373364 cites W2186902482 @default.
• W4311373364 cites W2192368460 @default.
• W4311373364 cites W23438228 @default.
• W4311373364 cites W2566983339 @default.
• W4311373364 cites W2591717879 @default.
• W4311373364 cites W2787358630 @default.
• W4311373364 cites W2953756046 @default.
• W4311373364 cites W2963316471 @default.
• W4311373364 cites W2996066981 @default.
• W4311373364 cites W3000125713 @default.
• W4311373364 cites W3025022288 @default.
• W4311373364 cites W3025742326 @default.
• W4311373364 cites W3026099517 @default.
• W4311373364 cites W3096245719 @default.
• W4311373364 cites W3119233878 @default.
• W4311373364 cites W3121466081 @default.
• W4311373364 cites W3154322879 @default.
• W4311373364 cites W3159001445 @default.
• W4311373364 cites W3213277274 @default.
• W4311373364 cites W4210955410 @default.
• W4311373364 cites W4213096024 @default.
• W4311373364 cites W4229003311 @default.
• W4311373364 cites W4232620598 @default.
• W4311373364 cites W4282822799 @default.
• W4311373364 cites W4289654165 @default.
• W4311373364 doi "https://doi.org/10.3390/cancers14246139" @default.
• W4311373364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36551623" @default.
• W4311373364 hasPublicationYear "2022" @default.
• W4311373364 type Work @default.
• W4311373364 citedByCount "0" @default.
• W4311373364 crossrefType "journal-article" @default.
• W4311373364 hasAuthorship W4311373364A5007520215 @default.
• W4311373364 hasAuthorship W4311373364A5016290433 @default.
• W4311373364 hasAuthorship W4311373364A5019218504 @default.
• W4311373364 hasAuthorship W4311373364A5021905751 @default.
• W4311373364 hasAuthorship W4311373364A5028776907 @default.
• W4311373364 hasAuthorship W4311373364A5028796603 @default.
• W4311373364 hasAuthorship W4311373364A5049296252 @default.
• W4311373364 hasAuthorship W4311373364A5061244847 @default.
• W4311373364 hasAuthorship W4311373364A5061536411 @default.
• W4311373364 hasAuthorship W4311373364A5061849776 @default.
• W4311373364 hasAuthorship W4311373364A5066490288 @default.
• W4311373364 hasAuthorship W4311373364A5071201254 @default.
• W4311373364 hasAuthorship W4311373364A5073675407 @default.
• W4311373364 hasAuthorship W4311373364A5074378971 @default.
• W4311373364 hasAuthorship W4311373364A5074394178 @default.
• W4311373364 hasAuthorship W4311373364A5090675713 @default.
• W4311373364 hasBestOaLocation W43113733641 @default.
• W4311373364 hasConcept C126322002 @default.
• W4311373364 hasConcept C146357865 @default.
• W4311373364 hasConcept C151730666 @default.
• W4311373364 hasConcept C17923572 @default.
• W4311373364 hasConcept C197934379 @default.
• W4311373364 hasConcept C207103383 @default.
• W4311373364 hasConcept C2776264508 @default.
• W4311373364 hasConcept C2778019345 @default.
• W4311373364 hasConcept C2778455285 @default.
• W4311373364 hasConcept C2778695046 @default.
• W4311373364 hasConcept C2778715236 @default.
• W4311373364 hasConcept C44249647 @default.
• W4311373364 hasConcept C50382708 @default.
• W4311373364 hasConcept C71924100 @default.
• W4311373364 hasConcept C86803240 @default.
• W4311373364 hasConcept C90924648 @default.
• W4311373364 hasConceptScore W4311373364C126322002 @default.
• W4311373364 hasConceptScore W4311373364C146357865 @default.
• W4311373364 hasConceptScore W4311373364C151730666 @default.
• W4311373364 hasConceptScore W4311373364C17923572 @default.

• next